×
About 20,064 results
Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results (S56.003)
https://n.neurology.org/content/88/16_Supplement/S56.003
Neurology

Apr 16th, 2017 - Data from two Phase 3 clinical studies investigating the efficacy and safety of ADS-5102 in Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID) were pooled to summarize results for the shared primary endpoint, Unified Dyskinesia Rating Scale (UDysRS) and its sub-components.

Metabotropic Glutamate Receptors for Parkinson's Disease Therapy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703788/
Parkinson's Disease;

May 28th, 2013 - Excessive glutamatergic signalling within the basal ganglia is implicated in the progression of Parkinson's disease (PD) and inthe emergence of dyskinesia associated with long-term treatment with L-DOPA. There is considerable research focus on the discovery and development of compounds that modulate glutamatergic signalling via glutamate receptors, as treatments for PD and L-DOPA-induced dyskin...

The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile
https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.22341
Movement Disorders;

Nov 20th, 2008 - We developed and tested a rating scale aimed to capture the essential features of dyskinesia in Parkinson's disease (PD). Although several scales assess selected attributes of PD‐dyskinesias, no comprehensive rating tool exists. Available rating scales were evaluated by the investigators and patient focus groups.

Levodopa‐induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600052/
Postgraduate Medical Journal;

Jun 4th, 2007 - Levodopa is the most effective drug for treating Parkinson's disease. However, long‐term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa dose increase the risk of development of levodopa‐induced dyskinesias (LID). The underlying mechanisms f...

Advances in understanding l-DOPA-induced dyskinesia
https://www.sciencedirect.com/science/article/abs/pii/S0959438808000068?via=ihub
Current Opinion in Neurobiology;

Mar 3rd, 2008 - The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disorders caused by either a deficiency or a hyperactivity of dopaminergic transmission in the basal ganglia. The degeneration of nigrostriatal DA neurons in Parkinson's disease causes poverty and slowness of movement. These symptoms are greatly improved by pharmacological DA replacement with l-3,4-dih...

The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations
https://www.tandfonline.com/doi/abs/10.1517/14656566.7.10.1399?src=recsys&journalCode=ieop20
Expert Opinion on Pharmacotherapy;

Jun 28th, 2006 - Levodopa is the most efficacious treatment in the management of Parkinson’s disease. Unfortunately, chronic use of traditional levodopa/dopa decarboxylase inhibitor formulations is associated with the development of complications, such as wearing-off and dyskinesia. In an attempt to avoid these complications, some physicians delay the introduction of levodopa or employ levodopa-sparing strategi...

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
https://www.dovepress.com/optimizing-levodopa-therapy-for-parkinsonrsquos-disease-with-levodopac-peer-reviewed-article-NDT
Neuropsychiatric Disease and Treatment;

Feb 7th, 2008 - After 40 years of clinical experience, levodopa remains the gold standard treatment for Parkinson’s disease (PD) despite the recent emergence of a host of new therapies. Some physicians are cautious when prescribing levodopa because of its association with motor complications. Evidence now suggests that levodopa-associated complications are a result of deep troughs in delivery of levodopa to th...

Subacute thyroiditis after SARS-CoV-2 infection
https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgaa276/5838793

Subacute thyroiditis (SAT) is a thyroid disease of viral or post-viral origin. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that began in Wuhan, China, has spread rapidly worldwide and Italy has been severely affected by this outbreak.

Top 20 Research Studies of 2019 for Primary Care Physicians
https://www.aafp.org/afp/2020/0515/p608.html

In 2019, regular surveillance of 110 English-language research journals identified 254 studies that met the criteria to become POEMs (patient-oriented evidence that matters). Physician members of the Canadian Medical Association rated these POEMs for their relevance to patients in their practices. This article summarizes the clinical questions and bottom-line answers from the top 20 POEMs of 20...

Indoor transmission of SARS-CoV-2
https://www.medrxiv.org/content/10.1101/2020.04.04.20053058v1.full.pdf

By early April 2020, the COVID-19 pandemic had infected nearly one million people and had spread to nearly all countries worldwide. It is essential to understand where and how SARS-CoV-2 is transmitted.

Re-thinking the Potential for Airborne Transmission of SARS-CoV-2
https://www.preprints.org/manuscript/202005.0126/v1

Evidence for the potential for airborne transmission of SARS-CoV-19 continues to accumulate, with important implications for healthcare workers, as well as the general public. Three lines of evidence support this conclusion. COVID-19

Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea
https://www.sfndt.org/sites/www.sfndt.org/files/medias/documents/Hong et al. Ann Lab Med Avril 2020.pdf
Annals of Laboratory Medicine;

The outbreak of coronavirus disease 2019 (COVID-19), which began in December 2019, is still ongoing in Korea, with >9,000 confirmed cases as of March 25, 2020. COVID-19 is a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection, and real-time reverse transcription-PCR is currently the most reliable diagnostic method for COVID-19 around the world. Korean Society for Laborato...

CDC Diagnostic Test for COVID-19
https://www.cdc.gov/coronavirus/2019-ncov/lab/testing.html

CDC has developed a new laboratory test kit for use in testing patient specimens for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. The test kit is called the “Centers for Disease Control and Prevention (CDC) 2019-Novel Coronavirus (2019-nCoV) Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panel.” It is intended for use with the Applied Biosys...

Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis
https://jamanetwork.com/journals/jama/article-abstract/2766163
JAMA

May 18th, 2020 - In this meta-analysis that included 12 trials with 92 135 participants for the primary outcome measure, blood pressure lowering with antihypertensive agents, compared with control, was associated with the development of a composite dementia or cognitive impairment outcome in 7.0% vs 7.5% of patients over a mean trial follow-up of 4.1 years, a difference that was statistically significant.

Policy Statement—Tobacco Use: A Pediatric Disease
https://pediatrics.aappublications.org/content/pediatrics/124/5/1474.full.pdf
American Academy of Pediatrics

Tobacco use and secondhand tobacco-smoke (SHS) exposure are major national and international health concerns. Pediatricians and other clinicians who care for children are uniquely positioned to assist patients and families with tobacco-use prevention and treatment. Understanding the nature and extent of tobacco use and SHS exposure is an essential first step toward the goal of eliminating toba...

Michael S. Hofman, MBBS, on Prostate Cancer: LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/michael-hofman-on-lupsma-vs-cabazitaxel-in-metastatic-castration-resistant-prostate-cancer/

May 29th, 2020 - Michael S. Hofman, MBBS, of the Peter MacCallum Cancer Centre, discusses phase II results from the ANZUP 1603 trial, which showed that in men with docetaxel-treated metastatic castration-resistant prostate cancer, LuPSMA was more active than cabazitaxel, with relatively fewer grade 3 and 4 adverse events and a more favorable PSA progression-free-survival (Abstract 5500).